This study, the VIGOR trial, raised the issue of the cardiovascular safety of the coxibs-a statistically insignificant increase in the incidence of myocardial infarctions was observed in patients on rofecoxib.
This study raised the issue of the cardiovascular safety of the coxibs. This study was the VIGOR trial. A statistically insignificant increase in the incidence of myocardial infarctions was observed in patients on rofecoxib.